Axcynsis Commences Phase 1 Clinical Trial in the United States
Singapore, February 1, 2026 — Axcynsis Therapeutics announced the commencement [...]
Axcynsis Therapeutics Announces Board Transition
Singapore, December 31, 2025 – Axcynsis Therapeutics announces that Dr. Thomas [...]
Axcynsis Therapeutics to Present Two Posters on Anti-CLDN6 and Anti-ALPP/ALPPL2 Antibody Therapeutics at American Association for Cancer Research (AACR) Annual Meeting 2025
Singapore, April 21, 2025 – Axcynsis Therapeutics is at the [...]
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
AT03-65 is the first program utilizing AxcynDOTTM, a proprietary payload [...]
Professor Patricia LoRusso joined Axcynsis Therapeutics’ Scientific Advisory Board
Singapore, December 31, 2024 - We are thrilled to announce [...]
Axcynsis Therapeutics won 2nd place in BCIC Annual Pitch Competition 2024
Axcynsis Therapeutics won 2nd place in BCIC Annual Pitch Competition [...]
Axcynsis Therapeutics TO PRESENT AT BIOTECH SHOWCASE™ 2024
Axcynsis, Next Generation of ADC Singapore, December 26, 2023 – [...]
Founder Dr Zou Bin Honoured with CEO of the Year
We are happy to share that our Founder and CEO, [...]
Axcynsis Therapeutics wins Best Antibody Conjugate Therapy Development Company 2023
We are honored and proud to receive the GHP [...]
WuXi AppTec BOLD: Spotlight I – The Next Wave of Cancer Therapeutics
Join our founder and CEO, Dr Zou Bin, together [...]